Hemophilia Treatment Market

Hemophilia Treatment Market by Indication (Type A, Type B), Therapy (Replacement (Recombinant, Plasma Derived), Route of Administration, End User - Global Forecast to 2027

Report Code: UC 1580 Oct, 2023, by marketsandmarkets.com

The global hemophilia treatment market is projected to reach USD ~15 billion by 2027 from USD 12 Billion in 2022, at a CAGR of 5% during the forecast period.

To know about the assumptions considered for the study, Request for Free Sample Report

The Hemophilia Treatment market has grown significantly over the last decade and is expected to witness continuous growth in the coming years. Increasing number of hemophilic patients worldwide is the major factor driving the market for recombinant and plasma derived factor VIII and factor IX, which are used to treat hemophilia. In addition, increased diagnosis rate and rise in the use of prophylactic treatment for hemophilia are expected to propel the growth of this market. However, the high cost of recombinant products, serious adverse effects associated with plasma derived products and stringent government regulations are hampering the growth of the global hemophilia treatment market to a certain extent.

In this report, the hemophilia treatment market is segmented by disease, product, route of administration, end user and region. Based on disease type, the hemophilia treatment market is mainly segmented into hemophilia A, hemophilia B and others. Hemophilia A and hemophilia B are divided into three segments, mild, moderate and severe depending on the level of infection by the disease. Based on product, the market is segmented into replacement therapy (recombinant and plasma derived), desmopressin, clot preserving medications, fibrin sealants, and others. Based on the route of administration, the market is segmented into injectable, nasal and oral.  The end user segment includes hospitals, clinics and others. The global hemophilia treatment market includes North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia Pacific (China, Japan, Rest of Asia Pacific) and Rest of the World regions.

To know about the assumptions considered for the study, download the pdf brochure

North America is the largest regional segment of the global hemophilia treatment market. However, the APAC region is expected to witness significant growth in the near future. This is primarily due to rising number of hemophilic patients and increasing awareness about technologically advanced products in the region. Moreover, owing to better diagnostic techniques, increasing prophylactic treatment and growing medical research in APAC region, the demand for recombinant and plasma derived products is likely to increase further. 

The global hemophilia market was a highly consolidated market as of 2013. However, new local players are emerging and taking efforts to intensify competition. In order to maintain their shares, leading players are continuously adopting various strategies. This increased competitiveness is expected to drive innovation in the market and thereby help the industry to solve existing challenges and meet the needs of the market.

The major players in the global hemophilia market are Bayer Healthcare (Germany), Octapharma AG (Switzerland), Novo Nordisk (Denmark), Kedrion (Italy), Pfizer Inc. (US), Biogen (US) among others.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 MARKETS COVERED
           1.2.2 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY
    2.1 RESEARCH DATA
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Key data from primary sources
    2.2 MARKET SIZE ESTIMATION
           2.2.1 BOTTOM-UP APPROACH
           2.2.2 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           5.2.1 DRIVERS
           5.2.2 RESTRAINTS
           5.2.3 OPPORTUNITIES
           5.2.4 CHALLENGES
    5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERíS BUSINESS
    5.4 PRICING ANALYSIS (BEST EFFORT BASIS)
    5.5 VALUE CHAIN ANALYSIS
    5.6 ECOSYSTEM ANALYSIS
    5.7 PATENT ANALYSIS
    5.8 KEY CONFERENCES AND EVENTS IN 2022-2023
    5.9 REGULATORY ANALYSIS
    5.10 PORTERíS FIVE FORCES ANALYSIS
    5.11 KEY STAKEHOLDER AND BUYING CRITERIA

6 HEMOPHILIA TREATMENT MARKET, BY DISEASE
    6.1 INTRODUCTION
    6.2 HEMOPHILIA A 
           6.2.1 MILD
           6.2.2 MODERATE
           6.2.3 SEVERE
    6.3 HEMOPHILIA B 
           6.3.1 MILD
           6.3.2 MODERATE
           6.3.3 SEVERE
    6.3 OTHERS 

7 HEMOPHILIA TREATMENT MARKET, BY PRODUCT*
    7.1 INTRODUCTION
    7.2 REPLACEMENT THERAPY
           6.3.1 RECOMBINANT
           6.3.2 PLASMA DERIVED
    7.3 DESMOPRESSIN
    7.4 CLOT-PRESERVING MEDICATIONS 
    7.5 FIBRIN SEALANTS
    7.6 OTHERS (GENE THERAPY, MONOCLONAL ANTIBODIES)

*Tentative segmentation, might change during course of the study

8 HEMOPHILIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
    8.1 INTRODUCTION
    8.2 INJECTABLE
    8.3 NASAL
    8.3 ORAL

9 HEMOPHILIA TREATMENT MARKET, BY END USER
    9.1 INTRODUCTION
    9.2 HOSPITALS
    9.3 CLINICS
    9.3 OTHERS

11 HEMOPHILIA TREATMENT MARKET, BY REGION
     11.1 INTRODUCTION
     11.2 NORTH AMERICA
             11.2.1 US
             11.2.2 CANADA
     11.3 EUROPE
             11.3.1 GERMANY
             11.3.2 UK
             11.3.3 FRANCE
             11.3.4 ITALY
             11.3.5 SPAIN
             11.3.6 REST OF EUROPE
     11.4 ASIA PACIFIC
             11.4.1 CHINA
             11.4.2 JAPAN
             11.4.3 REST OF ASIA PACIFIC
     11.5 REST OF THE WORLD

12 COMPETITIVE LANDSCAPE
     12.1 OVERVIEW
     12.2 KEY PLAYER STRATEGIES
     12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
     12.4 MARKET SHARE ANALYSIS, 2021
     12.5 COMPANY EVALUATION QUADRANT
     12.6 COMPANY EVALUATION QUADRANT Ė SME/START-UPS
     12.7 COMPANY GEOGRAPHIC FOOTPRINT
     12.8 COMPETITIVE SCENARIO

13 COMPANY PROFILES 
(Business overview, Products offered, Recent developments & MnM View)*
     13.1 BAYER HEALTHCARE
     13.2 BIOGEN
     13.4 BIOTEST AG
     13.5 CSL BEHRING
     13.6 FERRING B.V
     13.7 GENENTECH
     13.8 KEDRION
     13.9 NOVO NORDISK
     13.10 OCTAPHARMA
     13.11 PFIZER
     13.12 SANOFI SA
     13.13 SWEDISH ORPHAN BIOVITRUM AB

*Tenetative list. 20 key players will be profied. Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.

14 APPENDIX
     14.1 INSIGHTS FROM INDUSTRY EXPERTS
     14.2 DISCUSSION GUIDE0
     14.3 KNOWLEDGE STORE: MARKETSANDMARKETSí SUBSCRIPTION PORTAL
     14.4 AVAILABLE CUSTOMIZATIONS
     14.5 RELATED REPORTS
     14.6 AUTHOR DETAILS


Request for detailed methodology, assumptions & how numbers were triangulated.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).
2 9 7 1 5  
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
UC 1580
Available for Pre-Book
Choose License Type
Prebook Now
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Hemophilia Treatment Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback